AxxessBio partners with Gennisium in the area of Neonatology
October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®. Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon. Apnea in preterm